观点网讯:1月22日,上海复星医药(集团)股份有限公司发布联合公告,宣布其私有化复宏汉霖生物科技股份有限公司的建议终止。公告显示,合并于H股类别未在股东大会上获得批准,批准合并的特别决议案将不会生效,私有化事项不会进行。在临时股东大会上,特别决议案获得通过,赞成票数为4.35亿股,占比94.85%,反对票数为2284.65万股,占比4.98%,弃权票数为76.69股股,占比0.17%。在H股类别...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.